WAVE Life Sciences uses a proprietary synthetic chemistry platform to design stereopure nucleic acid therapeutics that precisely target underlying causes of rare genetic disorders. Its pipeline spans multiple oligonucleotide modalities, including antisense, exon-skipping and single-stranded RNAi, and includes allele-specific programs aimed at gain-of-function orphan diseases. The company says its stereopure chemistry eliminates complex stereoisomer mixtures to improve activity, stability, specificity and immunogenicity while reducing safety risks. WAVE is advancing candidates for Huntington’s disease and Duchenne muscular dystrophy and plans to file its first INDs by the end of 2016. Financially, the company recently completed an oversubscribed $66 million Series B preferred stock financing to fund continued platform development and pipeline advancement. WaVe Life Sciences develops stereopure nucleic acid therapeutics using a platform that produces single, precisely defined oligonucleotide structures with purportedly enhanced pharmaceutical properties versus conventional mixtures. Its chemistry is programmable during synthesis and applies across antisense, siRNA, mRNA and microRNA modalities. The company's pipeline includes antisense and exon-skipping drug candidates targeting diseases across multiple therapeutic areas and enables allele-specific targeting. WaVe plans to advance its programs through preclinical development and to continue strengthening its core technology capabilities. It maintains R&D facilities in Boston and Japan and was founded by Gregory Verdine and Takeshi Wada. The company recently closed an $18 million Series A to fund advancement of its pipeline.

Total raised

$84M

Funding rounds

2

Latest round

Series B

Latest activity

Aug 2015